Survival benefit of secondary prevention medical therapy in takotsubo cardiomyopathy: a Bayesian network meta-analysis
This review highlights the modest efficacy of secondary prevention medications in the management of TTC, as ACE or ARBs, beta-blockers, aspirin, and statins failed to demonstrate comparative mortality benefit. Randomized controlled trials are needed to confirm efficacy of pharmacotherapy in this vulnerable patient cohort.
Authors
- Aashray Gupta (ORCID: https://orcid.org/0000-0002-8038-0378)
- Stephen Bacchi (ORCID: https://orcid.org/0000-0001-5130-8628)
- Ammar Zaka (ORCID: https://orcid.org/0009-0004-4513-9601)
- Brandon Stretton (ORCID: https://orcid.org/0000-0002-7939-3489)
- Naim Mridha (ORCID: https://orcid.org/0000-0002-1214-8438)
- D. Mutahar
- Joshua G Kovoor
Institutions
- Bond University (AU)
- Royal Adelaide Hospital (AU)
- Royal North Shore Hospital (AU)
- Gold Coast Hospital (AU)
- Westmead Hospital (AU)
- Massachusetts General Hospital (US)
- Prince Charles Hospital (AU)
Publication Details
- Journal
- European Heart Journal Open
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1093/ehjopen/oeaf040
- Primary Topic
- Takotsubo Cardiomyopathy and Associated Phenomena
- Type
- article
- Field-Weighted Citation Impact
- 0.00